{"protocolSection":{"identificationModule":{"nctId":"NCT01067781","orgStudyIdInfo":{"id":"ELT208"},"organization":{"fullName":"Intercell USA, Inc.","class":"INDUSTRY"},"briefTitle":"Safety and Immunogenicity Study of Traveler's Diarrhea Vaccine Patch","officialTitle":"A Phase 2, Gender-Stratified, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Immunogenicity of a Two Vaccination Regimen With the Travelers' Diarrhea Vaccine System in Healthy Adults"},"statusModule":{"statusVerifiedDate":"2020-02","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2010-02"},"primaryCompletionDateStruct":{"date":"2010-09","type":"ACTUAL"},"completionDateStruct":{"date":"2012-03","type":"ACTUAL"},"studyFirstSubmitDate":"2010-02-09","studyFirstSubmitQcDate":"2010-02-11","studyFirstPostDateStruct":{"date":"2010-02-12","type":"ESTIMATED"},"resultsFirstSubmitDate":"2014-01-30","resultsFirstSubmitQcDate":"2014-01-30","resultsFirstPostDateStruct":{"date":"2014-03-13","type":"ESTIMATED"},"lastUpdateSubmitDate":"2020-02-04","lastUpdatePostDateStruct":{"date":"2020-02-10","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Intercell USA, Inc.","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"The purpose of this study is to evaluate and compare the safety and immune responses following a two vaccination regimen by transcutaneous immunization with heat-labile enterotoxin of E. coli (LT) patches or Placebo, with or without alcohol swabbing"},"conditionsModule":{"conditions":["Diarrhea"],"keywords":["Prevention of Travelers' Diarrhea"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"TRIPLE","whoMasked":["PARTICIPANT","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":600,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"1","type":"EXPERIMENTAL","description":"Two vaccination regimen with an LT patch (no swabbing)","interventionNames":["Biological: Heat-Labile Enterotoxin of E. coli (LT)"]},{"label":"2","type":"EXPERIMENTAL","description":"Two vaccination regimen with an LT patch (with swabbing)","interventionNames":["Biological: Heat-Labile Enterotoxin of E. coli (LT)"]},{"label":"3","type":"PLACEBO_COMPARATOR","description":"Two vaccination regimen with a placebo patch (no swabbing)","interventionNames":["Biological: Placebo"]},{"label":"4","type":"PLACEBO_COMPARATOR","description":"Two vaccination regimen with a placebo patch (with swabbing)","interventionNames":["Biological: Placebo"]}],"interventions":[{"type":"BIOLOGICAL","name":"Heat-Labile Enterotoxin of E. coli (LT)","description":"Travelers' Diarrhea Vaccine System","armGroupLabels":["1","2"]},{"type":"BIOLOGICAL","name":"Placebo","description":"Travelers' Diarrhea Vaccine System","armGroupLabels":["3","4"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Characterization and Comparison of the Safety of the TD Vaccine System: (1) Solicited and Unsolicited Adverse Events (AEs) (2) Clinical Laboratory Safety (3) Serious AEs","description":"Erythema, rash, pain, pruritus, hyperpigmentation, hypopigmentation and edema were solicited local AEs for the duration of the study. Fever, malaise, headache, and diarrhea were solicited systemic AEs for the first seven days following each vaccination; events reported outside this time frame were considered non-solicited.","timeFrame":"Day 0 to Day 180"}],"secondaryOutcomes":[{"measure":"Characterization and Comparison of Group LT-specific Immune Responses to the TD Vaccine System: Geometric Mean Titers","description":"LT immunoglobulin G (IgG) and immunoglobulin A (IgA)","timeFrame":"Day 0 to Day 180"},{"measure":"Characterization and Comparison of Group LT-specific Immune Responses to the TD Vaccine System: Geometric Mean Fold Ratios","description":"LT immunoglobulin G (IgG) and immunoglobulin A (IgA)","timeFrame":"Day 0 to Day 180"},{"measure":"Characterization and Comparison of Group LT-specific Immune Responses to the TD Vaccine System: Seroconversion Rates","description":"LT immunoglobulin G (IgG) and immunoglobulin A (IgA)","timeFrame":"Day 0 to Day 180"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. A female or male 18-64 (inclusive) years of age;\n2. In good health as determined by medical history and screening exam;\n3. Females who are post-menopausal, surgically sterile, or have a negative serum/urine pregnancy test at Day 0 and agree not to become pregnant for the duration of study.\n\nExclusion Criteria:\n\n1. Abnormalities at physical exam \\[as determined by the Toxicity Grading Scale (Grade 1-4)\\];\n2. Laboratory abnormalities \\[as determined by the Toxicity Grading Scale (Grade 1 4)\\] at screening;\n3. Participated in research involving investigational product within 30 days before planned date of first vaccination;\n4. Ever received investigational enterotoxigenic E. coli, LT, or LT (R192G) or NasalFlu, Berna Biotech, Ltd;\n5. Women who are pregnant or breastfeeding;\n6. Clinically significant underlying enteric, pulmonary, cardiac or renal disease;\n7. Current seizure disorder;\n8. Current use of immunosuppressive therapy (inhaled steroids are allowed);\n9. Known or suspected alcohol abuse or illicit drug use within the last year;\n10. Positive Serology for HIV-1, HIV-2, HbsAg, or HCV;\n11. Known allergies to any component of the vaccine including adhesives;\n12. An employee of the study site;\n13. An employee of Intercell (global) or an immediate family member;\n14. Visible tattoos or marks (tattoos/scars) at the vaccination areas that would prevent appropriate dermatologic monitoring of the vaccination sites;\n15. Receipt of any routine vaccinations within 7 days prior to, or following, the date of planned study vaccinations.","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"64 Years","stdAges":["ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Eric Sheldon, MD","affiliation":"Miami Research Associates","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Advanced Clinical Research Institute","city":"Anaheim","state":"California","zip":"92801","country":"United States","geoPoint":{"lat":33.83529,"lon":-117.9145}},{"facility":"Miami Research Associates","city":"South Miami","state":"Florida","zip":"33143","country":"United States","geoPoint":{"lat":25.7076,"lon":-80.29338}},{"facility":"Johnson County Clinical Trials","city":"Lenexa","state":"Kansas","zip":"66219","country":"United States","geoPoint":{"lat":38.95362,"lon":-94.73357}},{"facility":"Radiant Research","city":"Cincinnati","state":"Ohio","zip":"45249","country":"United States","geoPoint":{"lat":39.12711,"lon":-84.51439}},{"facility":"Clinical Trials of Texas","city":"San Antonio","state":"Texas","zip":"78229","country":"United States","geoPoint":{"lat":29.42412,"lon":-98.49363}}]},"referencesModule":{"seeAlsoLinks":[{"label":"Intercell Home Page","url":"http://www.valneva.com"}]}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Group 1: 37.5μg LT, No Swab","description":"Two vaccination regimen with an LT patch (no swabbing)\n\nHeat-Labile Enterotoxin of E. coli (LT): Travelers' Diarrhea Vaccine System"},{"id":"FG001","title":"Group 2: 37.5μg LT, Swab","description":"Two vaccination regimen with an LT patch (with swabbing)\n\nHeat-Labile Enterotoxin of E. coli (LT): Travelers' Diarrhea Vaccine System"},{"id":"FG002","title":"Group 3: 0μg LT, No Swab","description":"Two vaccination regimen with a placebo patch (no swabbing)\n\nPlacebo: Travelers' Diarrhea Vaccine System"},{"id":"FG003","title":"Group 4: 0μg LT, Swab","description":"Two vaccination regimen with a placebo patch (with swabbing)\n\nPlacebo: Travelers' Diarrhea Vaccine System"}],"periods":[{"title":"Up to Day 180","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"203"},{"groupId":"FG001","numSubjects":"199"},{"groupId":"FG002","numSubjects":"97"},{"groupId":"FG003","numSubjects":"101"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"173"},{"groupId":"FG001","numSubjects":"168"},{"groupId":"FG002","numSubjects":"89"},{"groupId":"FG003","numSubjects":"89"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"30"},{"groupId":"FG001","numSubjects":"31"},{"groupId":"FG002","numSubjects":"8"},{"groupId":"FG003","numSubjects":"12"}]}]},{"title":"180 to Day 720","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"173"},{"groupId":"FG001","numSubjects":"168"},{"groupId":"FG002","numSubjects":"89"},{"groupId":"FG003","numSubjects":"89"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","comment":"all subjects followed till Day180;if ongoing local AE, FU every 6 mths till AE resolved (max.Day720)","numSubjects":"3"},{"groupId":"FG001","comment":"all subjects followed till Day180;if ongoing local AE, FU every 6 mths till AE resolved (max.Day720)","numSubjects":"4"},{"groupId":"FG002","comment":"all subjects followed till Day180;if ongoing local AE, FU every 6 mths till AE resolved (max.Day720)","numSubjects":"0"},{"groupId":"FG003","comment":"all subjects followed till Day180;if ongoing local AE, FU every 6 mths till AE resolved (max.Day720)","numSubjects":"0"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"170"},{"groupId":"FG001","numSubjects":"164"},{"groupId":"FG002","numSubjects":"89"},{"groupId":"FG003","numSubjects":"89"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"safety population: includes all study subjects that were consented and received investigational study material (i.e., at least one vaccination)","groups":[{"id":"BG000","title":"Group 1: 37.5μg LT, No Swab","description":"Two vaccination regimen with an LT patch (no swabbing)\n\nHeat-Labile Enterotoxin of E. coli (LT): Travelers' Diarrhea Vaccine System"},{"id":"BG001","title":"Group 2: 37.5μg LT, Swab","description":"Two vaccination regimen with an LT patch (with swabbing)\n\nHeat-Labile Enterotoxin of E. coli (LT): Travelers' Diarrhea Vaccine System"},{"id":"BG002","title":"Group 3: 0μg LT, No Swab","description":"Two vaccination regimen with a placebo patch (no swabbing)\n\nPlacebo: Travelers' Diarrhea Vaccine System"},{"id":"BG003","title":"Group 4: 0μg LT, Swab","description":"Two vaccination regimen with a placebo patch (with swabbing)\n\nPlacebo: Travelers' Diarrhea Vaccine System"},{"id":"BG004","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"203"},{"groupId":"BG001","value":"199"},{"groupId":"BG002","value":"97"},{"groupId":"BG003","value":"101"},{"groupId":"BG004","value":"600"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"36.0","spread":"12.8"},{"groupId":"BG001","value":"35.3","spread":"13.1"},{"groupId":"BG002","value":"35.0","spread":"13.6"},{"groupId":"BG003","value":"35.7","spread":"12.8"},{"groupId":"BG004","value":"35.3","spread":"13.0"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"102"},{"groupId":"BG001","value":"99"},{"groupId":"BG002","value":"48"},{"groupId":"BG003","value":"51"},{"groupId":"BG004","value":"300"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"101"},{"groupId":"BG001","value":"100"},{"groupId":"BG002","value":"49"},{"groupId":"BG003","value":"50"},{"groupId":"BG004","value":"300"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Characterization and Comparison of the Safety of the TD Vaccine System: (1) Solicited and Unsolicited Adverse Events (AEs) (2) Clinical Laboratory Safety (3) Serious AEs","description":"Erythema, rash, pain, pruritus, hyperpigmentation, hypopigmentation and edema were solicited local AEs for the duration of the study. Fever, malaise, headache, and diarrhea were solicited systemic AEs for the first seven days following each vaccination; events reported outside this time frame were considered non-solicited.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Day 0 to Day 180","groups":[{"id":"OG000","title":"Group 1 & 2 Combined: 37.5µg LT Patch","description":"with or without swabbing"},{"id":"OG001","title":"Group 3 & 4 Combined: Placebo Patch (0µg LT)","description":"with or without swabbing"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"402"},{"groupId":"OG001","value":"198"}]}],"classes":[{"title":"Solicited Local Adverse Events (1st vaccination)","categories":[{"measurements":[{"groupId":"OG000","value":"318"},{"groupId":"OG001","value":"93"}]}]},{"title":"Solicited Local AEs (2nd vaccination)","categories":[{"measurements":[{"groupId":"OG000","value":"327"},{"groupId":"OG001","value":"62"}]}]},{"title":"Non-solicited Local AEs (1st vaccination)","categories":[{"measurements":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"3"}]}]},{"title":"Non-solicited Local AEs (2nd vaccination)","categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"3"}]}]},{"title":"Solicited Systemic AEs (overall)","categories":[{"measurements":[{"groupId":"OG000","value":"134"},{"groupId":"OG001","value":"59"}]}]},{"title":"Non-solicited Systemic AEs (overall)","categories":[{"measurements":[{"groupId":"OG000","value":"296"},{"groupId":"OG001","value":"148"}]}]},{"title":"Serious AEs","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"SECONDARY","title":"Characterization and Comparison of Group LT-specific Immune Responses to the TD Vaccine System: Geometric Mean Titers","description":"LT immunoglobulin G (IgG) and immunoglobulin A (IgA)","populationDescription":"the numbers analyzed differs from the Overall number analyzed because for this the Immunogenicity Evaluable Population (IEP) was used: includes all study subjects that were consented, randomized, received the assigned Treatments (both vaccinations) without significant protocol deviations and had blood drawn on Day 0, Day 21 and Day 35","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"titers","timeFrame":"Day 0 to Day 180","groups":[{"id":"OG000","title":"LT Patch Without Swabbing","description":"Two vaccination (Day 0 and Day 14) regimen with an LT patch (no swabbing), 37.5 mcg LT\n\nHeat-Labile Enterotoxin of E. coli (LT): Travelers' Diarrhea Vaccine System"},{"id":"OG001","title":"LT Patch With Swabbing","description":"Two vaccination (Day 0 and Day 14) regimen with an LT patch (with swabbing), 37.5 mcg LT\n\nSPS:Buffer-prepared site swabbed with a 70% isopropyl alcohol pad\n\nHeat-Labile Enterotoxin of E. coli (LT): Travelers' Diarrhea Vaccine System"},{"id":"OG002","title":"Placebo Patch Without Swabbing","description":"Two vaccination (Day 0 and Day 14) regimen with a placebo patch (no swabbing)\n\nPlacebo: Travelers' Diarrhea Vaccine System"},{"id":"OG003","title":"Placebo Patch With Swabbing","description":"Two vaccination (Day 0 and Day 14) regimen with a placebo patch (with swabbing)\n\nSPS:Buffer-prepared site swabbed with a 70% isopropyl alcohol pad\n\nPlacebo: Travelers' Diarrhea Vaccine System"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"182"},{"groupId":"OG001","value":"173"},{"groupId":"OG002","value":"92"},{"groupId":"OG003","value":"90"}]}],"classes":[{"title":"IgG Day 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"182"},{"groupId":"OG001","value":"173"},{"groupId":"OG002","value":"92"},{"groupId":"OG003","value":"90"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"442.21","lowerLimit":"386.83","upperLimit":"505.53"},{"groupId":"OG001","value":"421.20","lowerLimit":"368.78","upperLimit":"481.06"},{"groupId":"OG002","value":"435.64","lowerLimit":"360.89","upperLimit":"525.89"},{"groupId":"OG003","value":"344.40","lowerLimit":"282.43","upperLimit":"419.98"}]}]},{"title":"IgG Day 7","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"181"},{"groupId":"OG001","value":"172"},{"groupId":"OG002","value":"90"},{"groupId":"OG003","value":"89"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"455.68","lowerLimit":"402.07","upperLimit":"516.44"},{"groupId":"OG001","value":"437.80","lowerLimit":"380.75","upperLimit":"503.39"},{"groupId":"OG002","value":"426.28","lowerLimit":"352.98","upperLimit":"514.81"},{"groupId":"OG003","value":"348.13","lowerLimit":"289.47","upperLimit":"418.67"}]}]},{"title":"IgG Day 14","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"181"},{"groupId":"OG001","value":"172"},{"groupId":"OG002","value":"92"},{"groupId":"OG003","value":"90"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1042.41","lowerLimit":"862.90","upperLimit":"1259.26"},{"groupId":"OG001","value":"1148.98","lowerLimit":"940.12","upperLimit":"1404.24"},{"groupId":"OG002","value":"433.13","lowerLimit":"357.98","upperLimit":"524.06"},{"groupId":"OG003","value":"336.41","lowerLimit":"276.48","upperLimit":"409.34"}]}]},{"title":"IgG Day 21","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"182"},{"groupId":"OG001","value":"173"},{"groupId":"OG002","value":"92"},{"groupId":"OG003","value":"90"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2036.77","lowerLimit":"1678.75","upperLimit":"2471.14"},{"groupId":"OG001","value":"2537.89","lowerLimit":"2073.46","upperLimit":"3106.35"},{"groupId":"OG002","value":"447.47","lowerLimit":"371.36","upperLimit":"539.18"},{"groupId":"OG003","value":"404.66","lowerLimit":"332.68","upperLimit":"492.21"}]}]},{"title":"IgG Day 28","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"180"},{"groupId":"OG001","value":"172"},{"groupId":"OG002","value":"92"},{"groupId":"OG003","value":"90"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4010.55","lowerLimit":"3424.12","upperLimit":"4697.41"},{"groupId":"OG001","value":"4806.53","lowerLimit":"4057.60","upperLimit":"5693.69"},{"groupId":"OG002","value":"571.09","lowerLimit":"463.60","upperLimit":"703.49"},{"groupId":"OG003","value":"418.78","lowerLimit":"353.08","upperLimit":"496.69"}]}]},{"title":"IgG Day 35","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"182"},{"groupId":"OG001","value":"173"},{"groupId":"OG002","value":"92"},{"groupId":"OG003","value":"90"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4820.85","lowerLimit":"4121.82","upperLimit":"5638.42"},{"groupId":"OG001","value":"6005.34","lowerLimit":"5126.11","upperLimit":"7035.37"},{"groupId":"OG002","value":"573.03","lowerLimit":"471.04","upperLimit":"697.12"},{"groupId":"OG003","value":"421.34","lowerLimit":"359.37","upperLimit":"494.01"}]}]},{"title":"IgG Day 42","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"181"},{"groupId":"OG001","value":"170"},{"groupId":"OG002","value":"90"},{"groupId":"OG003","value":"90"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5229.02","lowerLimit":"4526.96","upperLimit":"6039.96"},{"groupId":"OG001","value":"5757.21","lowerLimit":"4949.95","upperLimit":"6696.11"},{"groupId":"OG002","value":"582.72","lowerLimit":"469.17","upperLimit":"723.76"},{"groupId":"OG003","value":"427.64","lowerLimit":"357.27","upperLimit":"511.86"}]}]},{"title":"IgG Day 56","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"177"},{"groupId":"OG001","value":"167"},{"groupId":"OG002","value":"90"},{"groupId":"OG003","value":"90"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5056.13","lowerLimit":"4380.77","upperLimit":"5835.60"},{"groupId":"OG001","value":"5633.07","lowerLimit":"4910.89","upperLimit":"6461.46"},{"groupId":"OG002","value":"588.69","lowerLimit":"484.87","upperLimit":"714.74"},{"groupId":"OG003","value":"411.26","lowerLimit":"340.90","upperLimit":"496.15"}]}]},{"title":"IgG Day 90","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"169"},{"groupId":"OG001","value":"161"},{"groupId":"OG002","value":"89"},{"groupId":"OG003","value":"89"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4833.84","lowerLimit":"4231.66","upperLimit":"5521.71"},{"groupId":"OG001","value":"4695.02","lowerLimit":"4085.96","upperLimit":"5394.87"},{"groupId":"OG002","value":"537.23","lowerLimit":"440.47","upperLimit":"655.24"},{"groupId":"OG003","value":"464.11","lowerLimit":"390.50","upperLimit":"551.61"}]}]},{"title":"IgG Day 180","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"161"},{"groupId":"OG001","value":"154"},{"groupId":"OG002","value":"85"},{"groupId":"OG003","value":"86"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2809.18","lowerLimit":"2440.40","upperLimit":"3233.67"},{"groupId":"OG001","value":"2843.59","lowerLimit":"2486.76","upperLimit":"3251.61"},{"groupId":"OG002","value":"498.20","lowerLimit":"404.73","upperLimit":"613.24"},{"groupId":"OG003","value":"419.89","lowerLimit":"354.80","upperLimit":"496.93"}]}]},{"title":"IgA Day 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"182"},{"groupId":"OG001","value":"173"},{"groupId":"OG002","value":"92"},{"groupId":"OG003","value":"90"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"72.71","lowerLimit":"65.10","upperLimit":"81.22"},{"groupId":"OG001","value":"67.06","lowerLimit":"60.62","upperLimit":"74.18"},{"groupId":"OG002","value":"63.00","lowerLimit":"55.53","upperLimit":"71.46"},{"groupId":"OG003","value":"69.52","lowerLimit":"59.90","upperLimit":"80.69"}]}]},{"title":"IgA Day 7","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"181"},{"groupId":"OG001","value":"172"},{"groupId":"OG002","value":"90"},{"groupId":"OG003","value":"89"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"74.30","lowerLimit":"66.09","upperLimit":"83.52"},{"groupId":"OG001","value":"65.29","lowerLimit":"58.70","upperLimit":"72.62"},{"groupId":"OG002","value":"62.26","lowerLimit":"54.81","upperLimit":"70.72"},{"groupId":"OG003","value":"70.77","lowerLimit":"60.62","upperLimit":"82.61"}]}]},{"title":"IgA Day 14","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"181"},{"groupId":"OG001","value":"172"},{"groupId":"OG002","value":"92"},{"groupId":"OG003","value":"90"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"130.89","lowerLimit":"112.10","upperLimit":"152.83"},{"groupId":"OG001","value":"132.33","lowerLimit":"111.62","upperLimit":"156.87"},{"groupId":"OG002","value":"59.70","lowerLimit":"53.47","upperLimit":"66.67"},{"groupId":"OG003","value":"69.79","lowerLimit":"59.78","upperLimit":"81.48"}]}]},{"title":"IgA Day 21","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"182"},{"groupId":"OG001","value":"173"},{"groupId":"OG002","value":"92"},{"groupId":"OG003","value":"90"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"183.42","lowerLimit":"155.55","upperLimit":"216.29"},{"groupId":"OG001","value":"175.05","lowerLimit":"147.46","upperLimit":"207.79"},{"groupId":"OG002","value":"65.82","lowerLimit":"56.12","upperLimit":"77.18"},{"groupId":"OG003","value":"69.91","lowerLimit":"59.83","upperLimit":"81.68"}]}]},{"title":"IgA Day 28","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"180"},{"groupId":"OG001","value":"172"},{"groupId":"OG002","value":"92"},{"groupId":"OG003","value":"90"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"290.95","lowerLimit":"251.96","upperLimit":"335.99"},{"groupId":"OG001","value":"294.68","lowerLimit":"252.19","upperLimit":"344.34"},{"groupId":"OG002","value":"67.52","lowerLimit":"57.86","upperLimit":"78.79"},{"groupId":"OG003","value":"76.00","lowerLimit":"64.41","upperLimit":"89.66"}]}]},{"title":"IgA Day 35","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"182"},{"groupId":"OG001","value":"173"},{"groupId":"OG002","value":"92"},{"groupId":"OG003","value":"90"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"284.26","lowerLimit":"247.37","upperLimit":"326.66"},{"groupId":"OG001","value":"286.88","lowerLimit":"245.46","upperLimit":"335.29"},{"groupId":"OG002","value":"69.84","lowerLimit":"60.23","upperLimit":"80.99"},{"groupId":"OG003","value":"74.91","lowerLimit":"63.19","upperLimit":"88.81"}]}]},{"title":"IgA Day 42","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"181"},{"groupId":"OG001","value":"170"},{"groupId":"OG002","value":"90"},{"groupId":"OG003","value":"90"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"248.33","lowerLimit":"214.74","upperLimit":"287.17"},{"groupId":"OG001","value":"261.53","lowerLimit":"223.84","upperLimit":"305.58"},{"groupId":"OG002","value":"67.45","lowerLimit":"58.30","upperLimit":"78.03"},{"groupId":"OG003","value":"71.97","lowerLimit":"61.24","upperLimit":"84.57"}]}]},{"title":"IgA Day 56","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"177"},{"groupId":"OG001","value":"167"},{"groupId":"OG002","value":"90"},{"groupId":"OG003","value":"90"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"229.76","lowerLimit":"198.94","upperLimit":"265.34"},{"groupId":"OG001","value":"232.70","lowerLimit":"200.49","upperLimit":"270.09"},{"groupId":"OG002","value":"70.11","lowerLimit":"59.62","upperLimit":"82.44"},{"groupId":"OG003","value":"78.60","lowerLimit":"66.30","upperLimit":"93.20"}]}]},{"title":"IgA Day 90","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"169"},{"groupId":"OG001","value":"161"},{"groupId":"OG002","value":"89"},{"groupId":"OG003","value":"89"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"168.18","lowerLimit":"144.93","upperLimit":"195.16"},{"groupId":"OG001","value":"166.85","lowerLimit":"142.94","upperLimit":"194.75"},{"groupId":"OG002","value":"61.79","lowerLimit":"53.98","upperLimit":"70.73"},{"groupId":"OG003","value":"70.93","lowerLimit":"60.92","upperLimit":"82.59"}]}]},{"title":"IgA Day 180","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"161"},{"groupId":"OG001","value":"154"},{"groupId":"OG002","value":"85"},{"groupId":"OG003","value":"86"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"120.12","lowerLimit":"104.49","upperLimit":"138.08"},{"groupId":"OG001","value":"124.50","lowerLimit":"107.41","upperLimit":"144.30"},{"groupId":"OG002","value":"56.00","lowerLimit":"50.00","upperLimit":"62.72"},{"groupId":"OG003","value":"61.30","lowerLimit":"53.98","upperLimit":"69.60"}]}]}]},{"type":"SECONDARY","title":"Characterization and Comparison of Group LT-specific Immune Responses to the TD Vaccine System: Geometric Mean Fold Ratios","description":"LT immunoglobulin G (IgG) and immunoglobulin A (IgA)","populationDescription":"the numbers analyzed differs from the Overall number analyzed because for this the Immunogenicity Evaluable Population (IEP) was used: includes all study subjects that were consented, randomized, received the assigned Treatments (both vaccinations) without significant protocol deviations and had blood drawn on Day 0, Day 21 and Day 35","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Geometric Mean Fold Ratios (GMFRs)","timeFrame":"Day 0 to Day 180","groups":[{"id":"OG000","title":"LT Patch Without Swabbing","description":"Two vaccination (Day 0 and Day 14) regimen with an LT patch (no swabbing), 37.5 mcg LT\n\nHeat-Labile Enterotoxin of E. coli (LT): Travelers' Diarrhea Vaccine System"},{"id":"OG001","title":"LT Patch With Swabbing","description":"Two vaccination (Day 0 and Day 14) regimen with an LT patch (with swabbing), 37.5 mcg LT\n\nSPS:Buffer-prepared site swabbed with a 70% isopropyl alcohol pad\n\nHeat-Labile Enterotoxin of E. coli (LT): Travelers' Diarrhea Vaccine System"},{"id":"OG002","title":"Placebo Patch Without Swabbing","description":"Two vaccination (Day 0 and Day 14) regimen with a placebo patch (no swabbing)\n\nPlacebo: Travelers' Diarrhea Vaccine System"},{"id":"OG003","title":"Placebo Patch With Swabbing","description":"Two vaccination (Day 0 and Day 14) regimen with a placebo patch (with swabbing)\n\nSPS:Buffer-prepared site swabbed with a 70% isopropyl alcohol pad\n\nPlacebo: Travelers' Diarrhea Vaccine System"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"182"},{"groupId":"OG001","value":"173"},{"groupId":"OG002","value":"92"},{"groupId":"OG003","value":"90"}]}],"classes":[{"title":"LT IgG Day 7","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"181"},{"groupId":"OG001","value":"172"},{"groupId":"OG002","value":"90"},{"groupId":"OG003","value":"89"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.02","lowerLimit":"0.95","upperLimit":"1.09"},{"groupId":"OG001","value":"1.04","lowerLimit":"0.97","upperLimit":"1.12"},{"groupId":"OG002","value":"0.96","lowerLimit":"0.89","upperLimit":"1.04"},{"groupId":"OG003","value":"1.02","lowerLimit":"0.95","upperLimit":"1.10"}]}]},{"title":"LT IgG Day 14","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"181"},{"groupId":"OG001","value":"172"},{"groupId":"OG002","value":"92"},{"groupId":"OG003","value":"90"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.37","lowerLimit":"2.01","upperLimit":"2.81"},{"groupId":"OG001","value":"2.73","lowerLimit":"2.26","upperLimit":"3.31"},{"groupId":"OG002","value":"0.99","lowerLimit":"0.92","upperLimit":"1.07"},{"groupId":"OG003","value":"0.98","lowerLimit":"0.90","upperLimit":"1.06"}]}]},{"title":"LT IgG Day 21","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"182"},{"groupId":"OG001","value":"173"},{"groupId":"OG002","value":"92"},{"groupId":"OG003","value":"90"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.61","lowerLimit":"3.76","upperLimit":"5.65"},{"groupId":"OG001","value":"6.03","lowerLimit":"4.86","upperLimit":"7.47"},{"groupId":"OG002","value":"1.03","lowerLimit":"0.94","upperLimit":"1.12"},{"groupId":"OG003","value":"1.17","lowerLimit":"1.05","upperLimit":"1.32"}]}]},{"title":"LT IgG Day 28","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"180"},{"groupId":"OG001","value":"172"},{"groupId":"OG002","value":"92"},{"groupId":"OG003","value":"90"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8.91","lowerLimit":"7.35","upperLimit":"10.81"},{"groupId":"OG001","value":"11.39","lowerLimit":"9.33","upperLimit":"13.9"},{"groupId":"OG002","value":"1.31","lowerLimit":"1.08","upperLimit":"1.58"},{"groupId":"OG003","value":"1.22","lowerLimit":"1.08","upperLimit":"1.37"}]}]},{"title":"LT IgG Day 35","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"182"},{"groupId":"OG001","value":"173"},{"groupId":"OG002","value":"92"},{"groupId":"OG003","value":"90"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"10.90","lowerLimit":"8.94","upperLimit":"13.29"},{"groupId":"OG001","value":"14.26","lowerLimit":"11.74","upperLimit":"17.31"},{"groupId":"OG002","value":"1.32","lowerLimit":"1.13","upperLimit":"1.53"},{"groupId":"OG003","value":"1.22","lowerLimit":"1.08","upperLimit":"1.38"}]}]},{"title":"LT IgG Day 42","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"181"},{"groupId":"OG001","value":"170"},{"groupId":"OG002","value":"90"},{"groupId":"OG003","value":"90"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"11.72","lowerLimit":"9.67","upperLimit":"14.21"},{"groupId":"OG001","value":"13.65","lowerLimit":"11.33","upperLimit":"16.44"},{"groupId":"OG002","value":"1.36","lowerLimit":"1.11","upperLimit":"1.66"},{"groupId":"OG003","value":"1.24","lowerLimit":"1.09","upperLimit":"1.41"}]}]},{"title":"LT IgG Day 56","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"177"},{"groupId":"OG001","value":"167"},{"groupId":"OG002","value":"90"},{"groupId":"OG003","value":"90"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"11.34","lowerLimit":"9.40","upperLimit":"13.68"},{"groupId":"OG001","value":"13.47","lowerLimit":"11.26","upperLimit":"16.10"},{"groupId":"OG002","value":"1.36","lowerLimit":"1.15","upperLimit":"1.60"},{"groupId":"OG003","value":"1.19","lowerLimit":"1.05","upperLimit":"1.36"}]}]},{"title":"LT IgG Day 90","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"169"},{"groupId":"OG001","value":"161"},{"groupId":"OG002","value":"89"},{"groupId":"OG003","value":"89"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"11.18","lowerLimit":"9.38","upperLimit":"13.32"},{"groupId":"OG001","value":"11.04","lowerLimit":"9.28","upperLimit":"13.15"},{"groupId":"OG002","value":"1.23","lowerLimit":"1.12","upperLimit":"1.36"},{"groupId":"OG003","value":"1.36","lowerLimit":"1.20","upperLimit":"1.54"}]}]},{"title":"LT IgG Day 180","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"161"},{"groupId":"OG001","value":"154"},{"groupId":"OG002","value":"85"},{"groupId":"OG003","value":"86"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6.49","lowerLimit":"5.41","upperLimit":"7.79"},{"groupId":"OG001","value":"6.58","lowerLimit":"5.58","upperLimit":"7.76"},{"groupId":"OG002","value":"1.15","lowerLimit":"1.01","upperLimit":"1.30"},{"groupId":"OG003","value":"1.23","lowerLimit":"1.09","upperLimit":"1.40"}]}]},{"title":"LT IgA Day 7","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"181"},{"groupId":"OG001","value":"172"},{"groupId":"OG002","value":"90"},{"groupId":"OG003","value":"89"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.02","lowerLimit":"0.96","upperLimit":"1.08"},{"groupId":"OG001","value":"0.98","lowerLimit":"0.93","upperLimit":"1.04"},{"groupId":"OG002","value":"1.00","lowerLimit":"0.93","upperLimit":"1.06"},{"groupId":"OG003","value":"1.02","lowerLimit":"0.97","upperLimit":"1.08"}]}]},{"title":"LT IgA Day 14","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"181"},{"groupId":"OG001","value":"172"},{"groupId":"OG002","value":"92"},{"groupId":"OG003","value":"90"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.81","lowerLimit":"1.59","upperLimit":"2.07"},{"groupId":"OG001","value":"1.99","lowerLimit":"1.69","upperLimit":"2.34"},{"groupId":"OG002","value":"0.95","lowerLimit":"0.88","upperLimit":"1.02"},{"groupId":"OG003","value":"1.00","lowerLimit":"0.94","upperLimit":"1.07"}]}]},{"title":"LT IgA Day 21","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"182"},{"groupId":"OG001","value":"173"},{"groupId":"OG002","value":"92"},{"groupId":"OG003","value":"90"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.52","lowerLimit":"2.17","upperLimit":"2.93"},{"groupId":"OG001","value":"2.61","lowerLimit":"2.20","upperLimit":"3.10"},{"groupId":"OG002","value":"1.04","lowerLimit":"0.92","upperLimit":"1.19"},{"groupId":"OG003","value":"1.01","lowerLimit":"0.93","upperLimit":"1.08"}]}]},{"title":"LT IgA Day 28","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"180"},{"groupId":"OG001","value":"172"},{"groupId":"OG002","value":"92"},{"groupId":"OG003","value":"90"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.03","lowerLimit":"3.49","upperLimit":"4.65"},{"groupId":"OG001","value":"4.38","lowerLimit":"3.72","upperLimit":"5.17"},{"groupId":"OG002","value":"1.07","lowerLimit":"0.96","upperLimit":"1.20"},{"groupId":"OG003","value":"1.09","lowerLimit":"1.00","upperLimit":"1.20"}]}]},{"title":"LT IgA Day 35","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"182"},{"groupId":"OG001","value":"173"},{"groupId":"OG002","value":"92"},{"groupId":"OG003","value":"90"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.91","lowerLimit":"3.41","upperLimit":"4.48"},{"groupId":"OG001","value":"4.28","lowerLimit":"3.63","upperLimit":"5.04"},{"groupId":"OG002","value":"1.11","lowerLimit":"0.99","upperLimit":"1.24"},{"groupId":"OG003","value":"1.08","lowerLimit":"0.98","upperLimit":"1.18"}]}]},{"title":"LT IgA Day 42","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"181"},{"groupId":"OG001","value":"170"},{"groupId":"OG002","value":"90"},{"groupId":"OG003","value":"90"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.41","lowerLimit":"2.96","upperLimit":"3.92"},{"groupId":"OG001","value":"3.92","lowerLimit":"3.34","upperLimit":"4.61"},{"groupId":"OG002","value":"1.07","lowerLimit":"0.97","upperLimit":"1.19"},{"groupId":"OG003","value":"1.04","lowerLimit":"0.93","upperLimit":"1.15"}]}]},{"title":"LT IgA Day 56","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"177"},{"groupId":"OG001","value":"167"},{"groupId":"OG002","value":"90"},{"groupId":"OG003","value":"90"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.16","lowerLimit":"2.76","upperLimit":"3.62"},{"groupId":"OG001","value":"3.53","lowerLimit":"3.03","upperLimit":"4.11"},{"groupId":"OG002","value":"1.13","lowerLimit":"1.01","upperLimit":"1.27"},{"groupId":"OG003","value":"1.13","lowerLimit":"1.01","upperLimit":"1.27"}]}]},{"title":"LT IgA Day 90","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"169"},{"groupId":"OG001","value":"161"},{"groupId":"OG002","value":"89"},{"groupId":"OG003","value":"89"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.32","lowerLimit":"2.03","upperLimit":"2.65"},{"groupId":"OG001","value":"2.58","lowerLimit":"2.22","upperLimit":"3.0"},{"groupId":"OG002","value":"0.98","lowerLimit":"0.92","upperLimit":"1.06"},{"groupId":"OG003","value":"1.02","lowerLimit":"0.92","upperLimit":"1.12"}]}]},{"title":"LT IgA Day 180","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"161"},{"groupId":"OG001","value":"154"},{"groupId":"OG002","value":"85"},{"groupId":"OG003","value":"86"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.66","lowerLimit":"1.46","upperLimit":"1.89"},{"groupId":"OG001","value":"1.89","lowerLimit":"1.65","upperLimit":"2.16"},{"groupId":"OG002","value":"0.92","lowerLimit":"0.83","upperLimit":"1.03"},{"groupId":"OG003","value":"0.90","lowerLimit":"0.80","upperLimit":"1.00"}]}]}]},{"type":"SECONDARY","title":"Characterization and Comparison of Group LT-specific Immune Responses to the TD Vaccine System: Seroconversion Rates","description":"LT immunoglobulin G (IgG) and immunoglobulin A (IgA)","populationDescription":"the numbers analyzed differs from the Overall number analyzed because for this the Immunogenicity Evaluable Population (IEP) was used: includes all study subjects that were consented, randomized, received the assigned Treatments (both vaccinations) without significant protocol deviations and had blood drawn on Day 0, Day 21 and Day 35","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Day 0 to Day 180","groups":[{"id":"OG000","title":"LT Patch Without Swabbing","description":"Two vaccination (Day 0 and Day 14) regimen with an LT patch (no swabbing), 37.5 mcg LT\n\nHeat-Labile Enterotoxin of E. coli (LT): Travelers' Diarrhea Vaccine System"},{"id":"OG001","title":"LT Patch With Swabbing","description":"Two vaccination (Day 0 and Day 14) regimen with an LT patch (with swabbing), 37.5 mcg LT\n\nSPS:Buffer-prepared site swabbed with a 70% isopropyl alcohol pad\n\nHeat-Labile Enterotoxin of E. coli (LT): Travelers' Diarrhea Vaccine System"},{"id":"OG002","title":"Placebo Patch Without Swabbing","description":"Two vaccination (Day 0 and Day 14) regimen with a placebo patch (no swabbing)\n\nPlacebo: Travelers' Diarrhea Vaccine System"},{"id":"OG003","title":"Placebo Patch With Swabbing","description":"Two vaccination (Day 0 and Day 14) regimen with a placebo patch (with swabbing)\n\nSPS:Buffer-prepared site swabbed with a 70% isopropyl alcohol pad\n\nPlacebo: Travelers' Diarrhea Vaccine System"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"182"},{"groupId":"OG001","value":"173"},{"groupId":"OG002","value":"92"},{"groupId":"OG003","value":"90"}]}],"classes":[{"title":"LT IgG Day 7","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"181"},{"groupId":"OG001","value":"172"},{"groupId":"OG002","value":"90"},{"groupId":"OG003","value":"89"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7.18","lowerLimit":"3.88","upperLimit":"11.97"},{"groupId":"OG001","value":"7.56","lowerLimit":"4.09","upperLimit":"12.58"},{"groupId":"OG002","value":"3.33","lowerLimit":"0.69","upperLimit":"9.43"},{"groupId":"OG003","value":"6.74","lowerLimit":"2.51","upperLimit":"14.10"}]}]},{"title":"LT IgG Day 14","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"181"},{"groupId":"OG001","value":"172"},{"groupId":"OG002","value":"92"},{"groupId":"OG003","value":"90"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"47.51","lowerLimit":"40.06","upperLimit":"55.05"},{"groupId":"OG001","value":"49.42","lowerLimit":"41.72","upperLimit":"57.13"},{"groupId":"OG002","value":"2.17","lowerLimit":"0.26","upperLimit":"7.63"},{"groupId":"OG003","value":"3.33","lowerLimit":"0.69","upperLimit":"9.43"}]}]},{"title":"LT IgG Day 21","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"182"},{"groupId":"OG001","value":"173"},{"groupId":"OG002","value":"92"},{"groupId":"OG003","value":"90"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"67.03","lowerLimit":"59.69","upperLimit":"73.81"},{"groupId":"OG001","value":"74.57","lowerLimit":"67.40","upperLimit":"80.87"},{"groupId":"OG002","value":"5.43","lowerLimit":"1.79","upperLimit":"12.23"},{"groupId":"OG003","value":"16.67","lowerLimit":"9.64","upperLimit":"26.00"}]}]},{"title":"LT IgG Day 28","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"180"},{"groupId":"OG001","value":"172"},{"groupId":"OG002","value":"92"},{"groupId":"OG003","value":"90"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"86.67","lowerLimit":"80.81","upperLimit":"91.27"},{"groupId":"OG001","value":"89.53","lowerLimit":"83.97","upperLimit":"93.68"},{"groupId":"OG002","value":"14.13","lowerLimit":"7.74","upperLimit":"22.95"},{"groupId":"OG003","value":"16.67","lowerLimit":"9.64","upperLimit":"26.00"}]}]},{"title":"LT IgG Day 35","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"182"},{"groupId":"OG001","value":"173"},{"groupId":"OG002","value":"92"},{"groupId":"OG003","value":"90"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"90.11","lowerLimit":"84.82","upperLimit":"94.03"},{"groupId":"OG001","value":"93.06","lowerLimit":"88.20","upperLimit":"96.36"},{"groupId":"OG002","value":"15.22","lowerLimit":"8.58","upperLimit":"24.21"},{"groupId":"OG003","value":"17.78","lowerLimit":"10.52","upperLimit":"27.26"}]}]},{"title":"LT IgG Day 42","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"181"},{"groupId":"OG001","value":"170"},{"groupId":"OG002","value":"90"},{"groupId":"OG003","value":"90"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"90.61","lowerLimit":"85.39","upperLimit":"94.43"},{"groupId":"OG001","value":"94.71","lowerLimit":"90.19","upperLimit":"97.55"},{"groupId":"OG002","value":"17.78","lowerLimit":"10.52","upperLimit":"27.26"},{"groupId":"OG003","value":"20.00","lowerLimit":"12.31","upperLimit":"29.75"}]}]},{"title":"LT IgG Day 56","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"177"},{"groupId":"OG001","value":"167"},{"groupId":"OG002","value":"90"},{"groupId":"OG003","value":"90"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"92.09","lowerLimit":"87.09","upperLimit":"95.61"},{"groupId":"OG001","value":"95.81","lowerLimit":"91.55","upperLimit":"98.30"},{"groupId":"OG002","value":"16.67","lowerLimit":"9.64","upperLimit":"26.00"},{"groupId":"OG003","value":"16.67","lowerLimit":"9.64","upperLimit":"26.00"}]}]},{"title":"LT IgG Day 90","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"169"},{"groupId":"OG001","value":"161"},{"groupId":"OG002","value":"89"},{"groupId":"OG003","value":"89"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"93.49","lowerLimit":"88.65","upperLimit":"96.71"},{"groupId":"OG001","value":"93.79","lowerLimit":"88.87","upperLimit":"96.98"},{"groupId":"OG002","value":"11.24","lowerLimit":"5.52","upperLimit":"19.69"},{"groupId":"OG003","value":"24.72","lowerLimit":"16.19","upperLimit":"35.00"}]}]},{"title":"LT IgG Day 180","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"161"},{"groupId":"OG001","value":"154"},{"groupId":"OG002","value":"85"},{"groupId":"OG003","value":"86"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"85.09","lowerLimit":"78.64","upperLimit":"90.21"},{"groupId":"OG001","value":"90.26","lowerLimit":"84.44","upperLimit":"94.45"},{"groupId":"OG002","value":"9.41","lowerLimit":"4.15","upperLimit":"17.71"},{"groupId":"OG003","value":"20.93","lowerLimit":"12.90","upperLimit":"31.05"}]}]},{"title":"LT IgA Day 7","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"181"},{"groupId":"OG001","value":"172"},{"groupId":"OG002","value":"90"},{"groupId":"OG003","value":"89"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.66","lowerLimit":"0.34","upperLimit":"4.77"},{"groupId":"OG001","value":"1.74","lowerLimit":"0.36","upperLimit":"5.01"},{"groupId":"OG002","value":"0.00","lowerLimit":"0.00","upperLimit":"4.02"},{"groupId":"OG003","value":"0.00","lowerLimit":"0.00","upperLimit":"4.06"}]}]},{"title":"LT IgA Day 14","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"181"},{"groupId":"OG001","value":"172"},{"groupId":"OG002","value":"92"},{"groupId":"OG003","value":"90"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"17.68","lowerLimit":"12.42","upperLimit":"24.03"},{"groupId":"OG001","value":"23.84","lowerLimit":"17.68","upperLimit":"30.92"},{"groupId":"OG002","value":"0.00","lowerLimit":"0.00","upperLimit":"3.93"},{"groupId":"OG003","value":"1.11","lowerLimit":"0.03","upperLimit":"6.04"}]}]},{"title":"LT IgA Day 21","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"182"},{"groupId":"OG001","value":"173"},{"groupId":"OG002","value":"92"},{"groupId":"OG003","value":"90"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"32.42","lowerLimit":"25.68","upperLimit":"39.74"},{"groupId":"OG001","value":"36.42","lowerLimit":"29.25","upperLimit":"44.06"},{"groupId":"OG002","value":"1.09","lowerLimit":"0.03","upperLimit":"5.91"},{"groupId":"OG003","value":"1.11","lowerLimit":"0.03","upperLimit":"6.04"}]}]},{"title":"LT IgA Day 28","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"180"},{"groupId":"OG001","value":"172"},{"groupId":"OG002","value":"92"},{"groupId":"OG003","value":"90"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"50.56","lowerLimit":"43.02","upperLimit":"58.07"},{"groupId":"OG001","value":"54.65","lowerLimit":"46.90","upperLimit":"62.24"},{"groupId":"OG002","value":"2.17","lowerLimit":"0.26","upperLimit":"7.63"},{"groupId":"OG003","value":"2.22","lowerLimit":"0.27","upperLimit":"7.80"}]}]},{"title":"LT IgA Day 35","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"182"},{"groupId":"OG001","value":"173"},{"groupId":"OG002","value":"92"},{"groupId":"OG003","value":"90"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"51.10","lowerLimit":"43.60","upperLimit":"58.57"},{"groupId":"OG001","value":"54.91","lowerLimit":"47.18","upperLimit":"62.48"},{"groupId":"OG002","value":"2.17","lowerLimit":"0.26","upperLimit":"7.63"},{"groupId":"OG003","value":"2.22","lowerLimit":"0.27","upperLimit":"7.80"}]}]},{"title":"LT IgA Day 42","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"181"},{"groupId":"OG001","value":"170"},{"groupId":"OG002","value":"90"},{"groupId":"OG003","value":"90"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"46.96","lowerLimit":"39.52","upperLimit":"54.51"},{"groupId":"OG001","value":"51.76","lowerLimit":"43.99","upperLimit":"59.48"},{"groupId":"OG002","value":"1.11","lowerLimit":"0.03","upperLimit":"6.04"},{"groupId":"OG003","value":"2.22","lowerLimit":"0.27","upperLimit":"7.80"}]}]},{"title":"LT IgA Day 56","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"177"},{"groupId":"OG001","value":"167"},{"groupId":"OG002","value":"90"},{"groupId":"OG003","value":"90"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"40.68","lowerLimit":"33.37","upperLimit":"48.30"},{"groupId":"OG001","value":"49.70","lowerLimit":"41.88","upperLimit":"57.53"},{"groupId":"OG002","value":"3.33","lowerLimit":"0.69","upperLimit":"9.43"},{"groupId":"OG003","value":"3.33","lowerLimit":"0.69","upperLimit":"9.43"}]}]},{"title":"LT IgA Day 90","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"169"},{"groupId":"OG001","value":"161"},{"groupId":"OG002","value":"89"},{"groupId":"OG003","value":"89"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"26.63","lowerLimit":"20.13","upperLimit":"33.96"},{"groupId":"OG001","value":"37.27","lowerLimit":"29.79","upperLimit":"45.23"},{"groupId":"OG002","value":"0.00","lowerLimit":"0.00","upperLimit":"4.06"},{"groupId":"OG003","value":"1.12","lowerLimit":"0.03","upperLimit":"6.10"}]}]},{"title":"LT IgA Day 180","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"161"},{"groupId":"OG001","value":"154"},{"groupId":"OG002","value":"85"},{"groupId":"OG003","value":"86"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"14.91","lowerLimit":"9.79","upperLimit":"21.36"},{"groupId":"OG001","value":"17.53","lowerLimit":"11.88","upperLimit":"24.47"},{"groupId":"OG002","value":"1.18","lowerLimit":"0.03","upperLimit":"6.38"},{"groupId":"OG003","value":"0.00","lowerLimit":"0.00","upperLimit":"4.20"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","eventGroups":[{"id":"EG000","title":"Group 1: 37.5μg LT, No Swab","description":"Two vaccination regimen with an LT patch (no swabbing)\n\nHeat-Labile Enterotoxin of E. coli (LT): Travelers' Diarrhea Vaccine System","seriousNumAffected":1,"seriousNumAtRisk":203,"otherNumAffected":197,"otherNumAtRisk":203},{"id":"EG001","title":"Group 2: 37.5μg LT, Swab","description":"Two vaccination regimen with an LT patch (with swabbing)\n\nHeat-Labile Enterotoxin of E. coli (LT): Travelers' Diarrhea Vaccine System","seriousNumAffected":3,"seriousNumAtRisk":199,"otherNumAffected":192,"otherNumAtRisk":199},{"id":"EG002","title":"Group 3: 0μg LT, No Swab","description":"Two vaccination regimen with a placebo patch (no swabbing)\n\nPlacebo: Travelers' Diarrhea Vaccine System","seriousNumAffected":0,"seriousNumAtRisk":97,"otherNumAffected":90,"otherNumAtRisk":97},{"id":"EG003","title":"Group 4: 0μg LT, Swab","description":"Two vaccination regimen with a placebo patch (with swabbing)\n\nPlacebo: Travelers' Diarrhea Vaccine System","seriousNumAffected":0,"seriousNumAtRisk":101,"otherNumAffected":92,"otherNumAtRisk":101}],"seriousEvents":[{"term":"Pancreatitis","organSystem":"Gastrointestinal disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":203},{"groupId":"EG001","numAffected":0,"numAtRisk":199},{"groupId":"EG002","numAffected":0,"numAtRisk":97},{"groupId":"EG003","numAffected":0,"numAtRisk":101}]},{"term":"Abortion spontaneous","organSystem":"Pregnancy, puerperium and perinatal conditions","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":203},{"groupId":"EG001","numAffected":1,"numAtRisk":199},{"groupId":"EG002","numAffected":0,"numAtRisk":97},{"groupId":"EG003","numAffected":0,"numAtRisk":101}]},{"term":"Bipolar disorder","organSystem":"Psychiatric disorders","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":203},{"groupId":"EG001","numAffected":1,"numAtRisk":199},{"groupId":"EG002","numAffected":0,"numAtRisk":97},{"groupId":"EG003","numAffected":0,"numAtRisk":101}]},{"term":"Accelerated hypertension","organSystem":"Vascular disorders","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":203},{"groupId":"EG001","numAffected":1,"numAtRisk":199},{"groupId":"EG002","numAffected":0,"numAtRisk":97},{"groupId":"EG003","numAffected":0,"numAtRisk":101}]}],"otherEvents":[{"term":"Headache","organSystem":"Nervous system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":33,"numAtRisk":203},{"groupId":"EG001","numAffected":36,"numAtRisk":199},{"groupId":"EG002","numAffected":19,"numAtRisk":97},{"groupId":"EG003","numAffected":18,"numAtRisk":101}]},{"term":"Malaise","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":18,"numAtRisk":203},{"groupId":"EG001","numAffected":25,"numAtRisk":199},{"groupId":"EG002","numAffected":9,"numAtRisk":97},{"groupId":"EG003","numAffected":6,"numAtRisk":101}]},{"term":"Diarrhea","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":33,"numAtRisk":203},{"groupId":"EG001","numAffected":40,"numAtRisk":199},{"groupId":"EG002","numAffected":14,"numAtRisk":97},{"groupId":"EG003","numAffected":14,"numAtRisk":101}]},{"term":"Vaccination site erythema","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":164,"numAtRisk":203},{"groupId":"EG001","numAffected":157,"numAtRisk":199},{"groupId":"EG002","numAffected":44,"numAtRisk":97},{"groupId":"EG003","numAffected":32,"numAtRisk":101}]},{"term":"Vaccination site rash","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":173,"numAtRisk":203},{"groupId":"EG001","numAffected":168,"numAtRisk":199},{"groupId":"EG002","numAffected":9,"numAtRisk":97},{"groupId":"EG003","numAffected":10,"numAtRisk":101}]},{"term":"Vaccination site hyperpigmentation","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":139,"numAtRisk":203},{"groupId":"EG001","numAffected":138,"numAtRisk":199},{"groupId":"EG002","numAffected":6,"numAtRisk":97},{"groupId":"EG003","numAffected":6,"numAtRisk":101}]},{"term":"Vaccination site edema","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":56,"numAtRisk":203},{"groupId":"EG001","numAffected":73,"numAtRisk":199},{"groupId":"EG002","numAffected":2,"numAtRisk":97},{"groupId":"EG003","numAffected":1,"numAtRisk":101}]},{"term":"Vaccination site pain","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":40,"numAtRisk":203},{"groupId":"EG001","numAffected":47,"numAtRisk":199},{"groupId":"EG002","numAffected":10,"numAtRisk":97},{"groupId":"EG003","numAffected":13,"numAtRisk":101}]},{"term":"Vaccination site pruritis","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":163,"numAtRisk":203},{"groupId":"EG001","numAffected":156,"numAtRisk":199},{"groupId":"EG002","numAffected":22,"numAtRisk":97},{"groupId":"EG003","numAffected":15,"numAtRisk":101}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true},"pointOfContact":{"title":"Head Clinical Developement","organization":"Valneva Austria GmbH","email":"info@valneva.com","phone":"0043120620","phoneExt":"0"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-11-09"},"conditionBrowseModule":{"meshes":[{"id":"D003967","term":"Diarrhea"}],"ancestors":[{"id":"D012817","term":"Signs and Symptoms, Digestive"},{"id":"D012816","term":"Signs and Symptoms"},{"id":"D013568","term":"Pathological Conditions, Signs and Symptoms"}]}},"hasResults":true}